Sartorius Stedim Biotech SA
PAR:DIM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Klabin SA
BOVESPA:KLBN4
|
BR |
|
Eternal Materials Co Ltd
TWSE:1717
|
TW |
|
Duckhorn Portfolio Inc
NYSE:NAPA
|
US |
|
Caixa Seguridade Participacoes SA
BOVESPA:CXSE3
|
BR |
|
H
|
H.B. Fuller Company
SWB:HB1
|
US |
|
Metasurface Technologies Holdings Ltd
HKEX:8637
|
SG |
|
Buana Lintas Lautan Tbk PT
IDX:BULL
|
ID |
Sartorius Stedim Biotech SA
Total Current Liabilities
Sartorius Stedim Biotech SA
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Sartorius Stedim Biotech SA
PAR:DIM
|
Total Current Liabilities
€1.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
20%
|
CAGR 10-Years
18%
|
|
|
Eurofins-Cerep SA
PAR:ALECR
|
Total Current Liabilities
€11m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
Sartorius Stedim Biotech SA
Glance View
Sartorius Stedim Biotech SA has been weaving the intricate threads of biotechnology innovation into a fabric of global influence and success. Established as a pivotal player in the biopharmaceutical industry, Sartorius Stedim Biotech has carved out a niche by offering sophisticated products and solutions that cater to the unique needs of biopharmaceutical manufacturers. The company’s portfolio is a testament to the fusion of scientific ingenuity and relentless pursuit of quality. Spanning filtration and purification solutions, fermentation equipment, and fluid management systems, their offerings ensure that complex biological drugs, including vaccines and monoclonal antibodies, are produced efficiently and safely. Sartorius Stedim Biotech’s endeavor is not just about supplying equipment; it’s about providing integrated solutions that optimize the entire production process, ensuring consistency, scalability, and compliance in industries bound by strict regulatory oversight. The company generated revenue through its comprehensive range of products and services that address every step of the biomanufacturing process. Their business model hinges on fostering long-term relationships with clients by offering tailored solutions that enhance productivity and reduce time-to-market for new therapies. Beyond direct sales of high-value equipment, Sartorius Stedim Biotech also capitalizes on recurring revenue streams generated from consumables and maintenance services essential for the ongoing operation of their systems. By continuously innovating and expanding its product lines, the company stays at the forefront of technological advancements, enabling clients to tackle the ever-evolving challenges of bioproduction. As the global biopharmaceutical industry surges forward, driven by increasing demand for biologics, Sartorius Stedim Biotech remains poised to maintain its role as an indispensable ally to firms dedicated to transforming the health landscape through revolutionary therapies.
See Also
What is Sartorius Stedim Biotech SA's Total Current Liabilities?
Total Current Liabilities
1.4B
EUR
Based on the financial report for Dec 31, 2025, Sartorius Stedim Biotech SA's Total Current Liabilities amounts to 1.4B EUR.
What is Sartorius Stedim Biotech SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
18%
Over the last year, the Total Current Liabilities growth was 50%. The average annual Total Current Liabilities growth rates for Sartorius Stedim Biotech SA have been 11% over the past three years , 20% over the past five years , and 18% over the past ten years .